Abcellera Biologics Inc (ABCL) - Total Liabilities
Based on the latest financial reports, Abcellera Biologics Inc (ABCL) has total liabilities worth $411.56 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ABCL long-term investment intensity to see how much of total assets are deployed in long-term investments.
Abcellera Biologics Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Abcellera Biologics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Abcellera Biologics Inc total assets.
Abcellera Biologics Inc Competitors by Total Liabilities
The table below lists competitors of Abcellera Biologics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bank of Hawaii Corporation
NYSE:BOH
|
USA | $22.33 Billion |
|
Black Stone Minerals LP
NYSE:BSM
|
USA | $252.40 Million |
|
Dongfeng Motor Group Company Limited
F:D4D
|
Germany | €163.85 Billion |
|
Gulfport Energy Operating Corp
NYSE:GPOR
|
USA | $1.27 Billion |
|
Shanghai Daimay Auto Interior
SHG:603730
|
China | CN¥2.57 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥453.98 Million |
|
Fujian Sunner Development Co Ltd
SHE:002299
|
China | CN¥13.21 Billion |
|
Tian Di Science & Technology Co Ltd
SHG:600582
|
China | CN¥26.42 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Abcellera Biologics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ABCL equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abcellera Biologics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abcellera Biologics Inc (2018–2025)
The table below shows the annual total liabilities of Abcellera Biologics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $390.05 Million | +28.11% |
| 2024-12-31 | $304.47 Million | -9.32% |
| 2023-12-31 | $335.78 Million | +9.15% |
| 2022-12-31 | $307.63 Million | +5.05% |
| 2021-12-31 | $292.84 Million | +67.31% |
| 2020-12-31 | $175.03 Million | +1222.36% |
| 2019-12-31 | $13.24 Million | +33.93% |
| 2018-12-31 | $9.88 Million | -- |
About Abcellera Biologics Inc
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more